SCHEMBL6489654

SCHEMBL6489654

Cc1ccc(-c2ccc(C)cc2C(=O)Nc2ccc(OCCc3cccc(NC(=O)OC(C)(C)C)n3)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APOB P04114 1/20 0.40
MTTP P55157 1/20 0.40
ITGB3 P05106 6/20 0.39
ITGAV P06756 6/20 0.39
ITGB1 P05556 5/20 0.39
ITGA5 P08648 5/20 0.39
SCN9A Q15858 2/20 0.39
CHRNB2 P17787 1/20 0.38
CHRNB4 P30926 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA4 P43681 1/20 0.38
SREBF2 Q12772 1/20 0.38
SIRT2 Q8IXJ6 1/20 0.38
AURKA O14965 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
SCN2A Q99250 1/20 0.36
SCN10A Q9Y5Y9 1/20 0.36
DGAT1 O75907 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6491507 0.94 MTTP (0.49) APOBMTTPSCN9ACHRNB2CHRNB4
SCHEMBL6490619 0.93 ITGB3 (0.39) ITGB3ITGAVITGB1ITGA5SCN9A
SCHEMBL6787323 0.93 POLB (0.42) ITGB3ITGAVITGB1ITGA5SCN9A
SCHEMBL6502751 0.90 CHRNB2 (0.44) ITGB3ITGAVITGB1ITGA5CHRNB2
SCHEMBL6488665 0.90 APOB (0.38) APOBMTTPITGB3ITGAVITGB1
SCHEMBL6492604 0.88 MTTP (0.42) APOBMTTPITGB3ITGAVITGB1
SCHEMBL6502934 0.87 MTTP (0.40) APOBMTTPITGB3ITGAVITGB1
SCHEMBL6490416 0.85 CHRNB2 (0.43) ITGB3ITGAVITGB1ITGA5CHRNB2
SCHEMBL6650060 0.85 ITGB3 (0.40) ITGB3ITGAVITGB1ITGA5CHRNB2
SCHEMBL6789234 0.84 SMO (0.47) APOBMTTPRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 APOB 1/4885MTTP 677/4885ITGB3 2225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.